BridgeMD
New treatment option for Secondary Hyperparathyroidism
Official title A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
ClinicalTrials.gov ID: NCT03969329
What this study is testing
What is Etelcalcetide?
Etelcalcetide is an investigational medicine, being studied as a potential treatment for secondary hyperparathyroidism.
Also referred to as Parsabiv - brand name.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to \< 18 years of age, with chronic kidney disease (CKD) on hemodialysis.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 17
You may be able to join if
- Participant's legally acceptable representative has provided informed consent when the participant is legally too young to provide informed consent...
- Male or female participants greater than or equal to 2 to less than 18 years of age at the time of enrollment.
- Targeted dry weight greater than or equal to 7 kg at the time of screening Week -1.
- Diagnosed with CKD and SHPT undergoing hemodialysis/hemodiafiltration TIW or four times a week (QIW) at the time of screening greater than or equal...
- Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values greater than 300 pg/mL during screening, on separate days and...
You likely can't join if
- Disease Related:
- History of congenital long QT syndrome, second or third degree heart block, ventricular tachyarrhythmia's, history of symptomatic ventricular...
- Anticipated or scheduled parathyroidectomy during the trial period.
- Anticipated or scheduled kidney transplant during the trial period.
- Participant has received a parathyroidectomy within 6 months prior to enrollment.
- Other Medical Conditions:
See the full eligibility criteria
Who can join
- Participant's legally acceptable representative has provided informed consent when the participant is legally too young to provide informed consent and the participant has provided written assent based on local...
- Male or female participants greater than or equal to 2 to less than 18 years of age at the time of enrollment.
- Targeted dry weight greater than or equal to 7 kg at the time of screening Week -1.
- Diagnosed with CKD and SHPT undergoing hemodialysis/hemodiafiltration TIW or four times a week (QIW) at the time of screening greater than or equal to 1 month.
- Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values greater than 300 pg/mL during screening, on separate days and within 2 weeks of enrollment obtained from the central laboratory during...
- Serum corrected Ca value greater than or equal to 9.0 mg/dL obtained from the central laboratory during screening.
- Dialysate Ca level greater than or equal to 2.5 mEq/L for at least 1 month prior to screening and throughout the duration of the trial.
- participant receiving active vitamin D sterols must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through enrollment, and be expected to...
- participant receiving phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through enrollment, and be expected to maintain...
- Subject receiving Ca supplements must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through enrollment, and be expected to maintain stable...
- SHPT not due to vitamin D deficiency, per investigator assessment.
What rules you out
- Disease Related:
- History of congenital long QT syndrome, second or third degree heart block, ventricular tachyarrhythmia's, history of symptomatic ventricular dysrhythmias Torsades de Pointes or other conditions associated with...
- Anticipated or scheduled parathyroidectomy during the trial period.
- Anticipated or scheduled kidney transplant during the trial period.
- Participant has received a parathyroidectomy within 6 months prior to enrollment.
- Other Medical Conditions:
- Current malignancy or history of other malignancy, except non-melanoma skin cancers within the last 5 years.
- Prior/Concomitant Therapy:
- Use of concomitant medications that may prolong the QTc (eg, ondansetron, albuterol, sotalol, amiodarone, erythromycin, or clarithromycin). Refer to CredibleMeds.org for guidance. Certain medications may be allowed...
- Receipt of cinacalcet therapy within 30 days prior to screening and through enrollment.
- Any previous use of etelcalcetide prior to screening and through enrollment (Original protocol, Amendment 1, and Amendment 2 only).
- Receipt of etelcalcetide therapy within 6 months prior to screening assessments and through enrollment (Amendment 3 and later only).
- All herbal medicines (eg, St. John's wort), vitamins, and supplements consumed by the participant within the 30 days prior to enrollment, and continuing use if applicable, will be reviewed by the Principal Investigator...
- Use of any over-the-counter or prescription medications within the 14 days or 5 half-lives (whichever is longer) prior to enrollment that are not established therapies for participants with renal disease or other...
- Prior/Concurrent Clinical Trial Experience:
- Currently receiving treatment in another investigational device or drug trial, or less than 30 days since ending treatment on another investigational device or drug trial(s). Other investigational procedures while...
- Diagnostic Assessments During Screening:
- Participant has significant abnormalities on the most recent central laboratory test during the screening period prior to enrollment per the Investigator including but not limited to the following: a. Serum transaminase...
- Corrected QT interval greater than 500 ms, using Bazett's formula.
- Corrected QT interval greater than or equal to 450 to less than or equal to 500 ms, using Bazett's formula, unless written permission to enroll is provided by the investigator after consultation with a pediatric...
- Participant has a clinically significant ECG abnormality (eg, unstable arrhythmia) during screening that, in the opinion of the investigator, could pose a risk to participant safety or interfere with the trial...
- Within the 3 Months Prior to Screening:
- New onset or worsening of a pre-existing seizure disorder.
- Participants on anti-convulsant medication must be on a stable and therapeutic dose for 3 months prior to screening (if blood level monitoring is clinically available, then the participant must have a therapeutic blood...
- Female participant is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 3 months after the last dose of etelcalcetide. (Females of childbearing potential...
- Female participants of childbearing potential unwilling to use 1 highly effective or acceptable method of effective contraception during treatment and for an additional 3 months after the last dose of investigational...
- Female participants of childbearing potential with a positive pregnancy test assessed at screening by a serum pregnancy test.
- Participant has known sensitivity to etelcalcetide or excipients to be administered during dosing.
- Participant likely to not be available to complete all protocol-required trial visits or procedures, and/or to comply with all required trial procedures to the best of the participant and investigator's knowledge.
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) or unacceptable physical findings, that, in the opinion of the investigator or Amgen...
- Participant has previously entered this trial or previously received treatment with etelcalcetide (Original protocol, Amendment 1 and Amendment 2 only).
- Participant previously has entered this trial (Amendment 3 and later only).
- Anemia, which in the opinion of the investigator makes it not advisable to undergo sequential blood draws.
- History of unstable chronic heart failure within the last 1 year prior to screening.
The study team makes the final eligibility decision.
Where it's taking place
- Ghent, Belgium
- Prague, Czechia
- Bron, France
- Paris, France
- Bonn, Germany
- Cologne, Germany
- Hamburg, Germany
- Hanover, Germany
- Heidelberg, Germany
- Athens, Greece
- Thessaloniki, Greece
- Budapest, Hungary
- Szeged, Hungary
- Florence, Italy
- Vilinus, Lithuania
- Krakow, Poland
- Porto, Portugal
- Seville, Andalusia, Spain
- Barcelona, Catalonia, Spain
- Glasgow, United Kingdom
+ 3 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ghent, Belgium; Prague, Czechia; Bron, France; Paris, France; Bonn, Germany; Cologne, Germany and 17 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.